Related Experiment Video
Updated: Jul 23, 2026

05:57
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
4.5K
New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab
P Bortoluzzi1, S Ferrucci2, D Galimberti3
1Postgraduate School of Dermatology and Venereology, Università degli Studi, Milan, Italy.
The British Journal of Dermatology
|August 25, 2021
Abstract:
Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre-existing ocular alterations belonging to the spectrum of AKC.

